secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2023-07-20T23:59:59+00:00
Accession:  0001728117-23-000094
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio raises $212M in private placement; discloses interim TORREY OLE data and PROSERA Phase 3 design
--------------------------------------------------------------------------------

- Sold 129.9M shares + warrants to purchase 32.5M shares at combined price $1.63125 per unit for gross proceeds ~$212M.
- Warrants exercisable at $2.04/share, immediately exercisable, expire July 24, 2028.
- Net proceeds to fund seralutinib development/commercialization and working capital.
- Participation from NEA, EcoR1, Armistice, Farallon, Madison Avenue Partners, and others.
- Interim TORREY OLE data and PROSERA Phase 3 design disclosed via separate 8-K; conference call July 25.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811723000094/0001728117-23-000094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811723000094/goss-20230719.htm
  HTML page:      https://secwatch.observer/filing/0001728117-23-000094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer